Brief: Atai Life Sciences Announces First Patient Dosed In Elumina, The Phase 2 Clinical Trial Of VLS-01 For Treatment-Resistant Depression
11/03/2025 11:09
March 11 (Reuters) - ATAI Life Sciences NV 9VC.DE: ATAI LIFE SCIENCES ANNOUNCES FIRST PATIENT DOSED IN ELUMINA, THE PHASE 2 CLINICAL TRIAL OF VLS-01 FOR TREATMENT-RESISTANT DEPRESSION ATAI LIFE SCIENCES NV - TOPLINE RESULTS FROM PHASE 2 ELUMINA TRIAL EXPECTED Q1 2026 Source text: ID:nGNX4zk9DR Further company coverage: 9VC.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AtaiBeckley
See all newsFDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM